Antidiarrheal and Cardio-Depressant Effects of *Himalaiella heteromalla* (D.Don) Raab-Straube: In Vitro, In Vivo, and In Silico Studies

Fatima Saqib 1,*, Faisal Usman 1, Shehneela Malik 1, Naheed Bano 2, Najm Ur-Rahman 3, Muhammad Riaz 3, Romina Alina Marc (Vlaic) 4,* and Crina Carmen Mureșan 4

1 Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60000, Pakistan; faisal.usman@bzu.edu.pk (F.U.); shehneelamalik1@gmail.com (S.M.)
2 Faculty of Veterinary and Animal Sciences, MNS-University of Agriculture, Multan 60000, Pakistan; bnaheed61@gmail.com
3 Department of Pharmacy, Shaheed Benazir Bhutto University, Sheringal 18050, Pakistan; najm@sbbu.edu.pk (N.U.-R.); pharmariaz@gmail.com (M.R.)
4 Food Engineering Department, Faculty of Food Science and Technology, University of Agricultural Sciences and Veterinary Medicine, 400372 Cluj-Napoca, Romania; crina.muresan@usamvcluj.ro
* Correspondence: fatima.saqib@bzu.edu.pk (F.S.); romina.vlaic@usamvcluj.ro (R.A.M.)

Abstract: *Himalaiella heteromalla* (D.Don) Raab-Straube is a commonly used remedy against various diseases. Crude extract and fractions of *H. heteromalla* were investigated for a gastrointestinal, bronchodilator, cardiovascular, and anti-inflammatory activities. *H. heteromalla* crude extract (Hh.Cr) relaxed spontaneous contractions and K⁺ (80 mM)-induced contraction in jejunum tissue dose-dependently. The relaxation of K⁺ (80 mM) indicates the presence of Ca²⁺ channel blocking (CCB) effect, which was further confirmed by constructing calcium response curves (CRCs) as they caused rightward parallel shift of CRCs in a manner comparable to verapamil, so the spasmolytic effect of Hh.Cr was due to its CCB activity. Application of Hh.Cr on CCh (1 µM) and K⁺ (80 mM)-induced contraction in tracheal preparation resulted in complete relaxation, showing its bronchodilator effect mediated through Ca²⁺ channels and cholinergic antagonist activity. Application of Hh.Cr on aortic preparations exhibited vasorelaxant activity through angiotensin and α-adrenergic receptors blockage. It also showed the cardio suppressant effect with negative chronotropic and inotropic response in paired atrium preparation. Similar effects were observed in in vivo models, i.e., decreased propulsive movement, wet feces, and inhibition of edema formation.

Keywords: antidiarrheal; calcium ion channel; cardio-depressant; *Himalaiella heteromalla*

1. Introduction

*Himalaiella heteromalla* (D.Don) Raab-Straube (*Asteraceae*), commonly known as Batula, is found in low-temperature regions of Asia, Europe, and North America [1]. *Himalaiella heteromalla* is a rich source of chlorojanerin, arctigenin [2] glycosides, alkaloids, terpenoids, saponins, flavonoids, sesquiterpene lactones, and arctiin [3]. Gao et al. [4] and Kang et al. [5] reported arctigenin and its glycoside, arctiin, have anti-inflammatory activities by inhibiting iNOS and exerting vasodilation effect, while Hayashi et al. [6] reported the anti-viral activity against influenza A virus.

Traditionally, *H. heteromalla* is used in herbal products to treat fever, menstruation, circulation, pain, and rheumatic arthritis [7]. It is used in wounds, cuts, and fever [8]. The leaf paste and mustard oil mixture are used for wounds and leukoderma. It has carminative property, used for coeliac diseases [9,10]. It is used to remedy burning parts of the body, menstrual problems, piles, psoriasis, rheumatoid arthritis, cardiotoxic cough with cold, and altitude sickness, and provide anticancer and anti-fatigue actions [11]. It is used as an
anti-inflammatory and prevents ischemic stroke [3]. Therefore, *H. heteromalla* was investigated in in vitro, in vivo, and in silico models as a possible tool to treat gastrointestinal, cardiovascular, respiratory, and inflammatory ailments.

2. Results

2.1. Phytochemical Analysis of Himalaiella heteromalla

The preliminary phytochemical analysis of Hh.Cr confirmed the presence of glycosides, saponins, alkaloids, and flavonoids.

2.2. HPLC Separation of Phenolic Acids and Flavonoids

The separation factor and resolution of all separated compounds were >1.0 and >1.5, respectively. The reproducibility of separate components was also good with RSD < 2% (run to run) and 2.7% (day to day) [12]. The HPLC chromatograms for the identified phenolic and flavonoid compounds are shown in Figure 1, and Table 1 presents the phenolic and flavonoid compounds identified in Hh.Cr. The most abundant phenolic compounds were gallic acid (184.98 µg/g), hydroxybenzoic acid (6.8 µg/g), and vanillic acid (8.1 µg/g); while the identified flavonoid compound was catechin (160.37 µg/g).

![Figure 1. HPLC chromatogram of (A) standard phenolic compounds (B) Hh.Cr.](image)

Table 1. Phenolic and flavonoid compounds of Hh.Cr.

| Sr.No. | Compound     | Retention Time (min) | Concentration (µg/g) |
|--------|--------------|----------------------|----------------------|
| 1.     | Gallic Acid  | 2.7                  | 184.98               |
| 2.     | Catechin     | 3.3                  | 160.37               |
| 3.     | HB acid      | 6.6                  | 22.80                |
| 4.     | Vanillic acid| 8.1                  | 9.08                 |

2.3. Effect on Jejunum Preparations

The Hh.Cr and its ethyl acetate (Hh.Ea) fraction showed the relaxant effect on exposure to the rhythmic contraction of jejunum preparations in organ bath within concentration range 0.01 to 0.3 mg/mL with EC_{50} 0.06 mg/mL (95% CI: 0.045–0.080 mg/mL; n = 5) and 0.01 to 0.1 mg/mL with EC_{50} 0.032 mg/mL (95% CI: 0.021–0.051 mg/mL; n = 5),
respectively similar to verapamil with EC$_{50}$ 0.42 µM (95% CI: 0.22–1.27), whereas aqueous fraction *H. heteromalla* failed to complete relaxation of spontaneous contractions of jejunum preparations. Hh.Cr and Hh.Ea also caused a complete relaxation of K$^+$ (80 mM) induced spastic contractions at 1 mg/mL with EC$_{50}$ 0.13 mg/mL (95% CI: 0.088–0.220 mg/mL; n = 5) and 0.3 mg/mL with EC$_{50}$ 0.06 mg/mL (95% CI: 0.045–0.0.089 mg/mL; n = 5), respectively similar to verapamil with EC$_{50}$ 0.251 µM (95% CI: 0.082–0.784). Furthermore, Hh.Cr showed a rightward shift of calcium CRCs which confirm the presence calcium ion channel blockade activity in Hh.Cr, similar to verapamil (Figures 2 and 3).

**Figure 2.** (A) Control spontaneous contraction. Effect of (B) crude extract (Hh.Cr), (C) Ethyl acetate fraction (Ea.Hh), (D) Aqueous fraction (Ea.Aq), and (E) verapamil on spontaneous. Effect of (F) crude extract (Hh.Cr), (G) Ethyl acetate fraction (Ea.Hh), (H) Aqueous fraction (Ea.Aq), and (I) verapamil on K$^+$ Induced Contraction on rabbit jejunum preparations.
For Peer Review

(Hh.Aq) exerted partially relaxation of K⁺ (95% CI: 0.024–0.072 mg/mL; n = 5), respectively. Hh.Cr and its Hh.Ea fraction also relaxed the K⁺ (95% CI: 0.076–0.302 mg/mL; n = 5), respectively. Similarly, verapamil also caused relaxation of K⁺. The Hh.Cr and its ethyl acetate (Hh.Ea) fraction showed the relaxant effect on tracheal preparations. Values are expressed as mean ± SEM.

2.4. Effect on Tracheal Preparations

The Hh.Cr and its ethyl acetate (Hh.Ea) fraction showed the relaxant effect on tracheal preparations, when exposed K⁺ (80 mM) and CCh (1 µM)-induced contractions. Hh.Cr and its Hh.Ea fraction relaxed the K⁺ (80 mM) induce contractions at 0.3 mg/mL with EC₅₀ 0.19 mg/mL (95% CI: 0.099–0.452; n = 5) and 0.1 mg/mL with EC₅₀ 0.042 mg/mL (95% CI: 0.024–0.072 mg/mL; n = 5), respectively. Hh.Cr and its Hh.Ea fraction also relaxed the CCh (1 µM) induce contractions at 1 mg/mL with EC₅₀ 0.23 mg/mL (95% CI: 0.158–0.357 mg/mL; n = 5) and 0.3 mg/mL with EC₅₀ 0.155 mg/mL (95% CI: 0.076–0.302 mg/mL; n = 5), respectively. Similarly, verapamil also caused relaxation of K⁺ (80 mM) and CCh (1 µM) induced contractions with respective EC₅₀ 0.82 µM (95% CI: 0.82–0.82 µM) and EC₅₀ values of 2.35 µM (95% CI: 0.32–2.39 µM). The aqueous fraction (Hh.Aq) exerted partially relaxation of K⁺ (80 mM) and CCh (1 µM)-induced contractions on tracheal preparation (Figure 4).

![Figure 3. Effect of crude extract (Hh.Cr) Ethyl acetate fraction (Ea.Hh) and aqueous fraction (Ea.Aq) on (A) spontaneous contraction and (B) K⁺ (80 mM)-induce Contraction on rabbit jejunum preparations. (C) Effect of verapamil on spontaneous and K⁺ induced contraction on rabbit jejunum preparations. Dose–response curves of Ca++ in the presence and absence of (D) Hh.Cr (E) verapamil in the isolated rabbit jejunum preparations. Values are expressed as mean ± SEM.](image-url)
2.5. Effect on Aortic Preparations

The crude extract (Hh.Cr) and its ethyl acetate (Hh.Ea) fraction showed the relaxant effect on aortic preparations, when exposed K+ (80 mM) and PE (1 μM) induced contractions. Hh.Cr and its Hh.Ea fraction relaxed the K+ (80 mM) induce contractions at 3 mg/mL with EC50 2.88 mg/mL (95% CI: 2.106–4.156 mg/mL; n = 5) and 1 mg/mL with EC50 0.148 mg/mL (95% CI: 0.09491–0.2332 mg/mL; n = 5), respectively. Hh.Cr and its Hh.Ea fraction also relaxed the PE (1 μM) induce contractions at 5 mg/mL with EC50 15.53 mg/mL (95% CI: 7.965 to 62.27 mg/mL; n = 5) and 3 mg/mL with EC50 4.2 mg/mL (95% CI: 2.991 to 6.670 mg/mL; n = 5), respectively. Similarly, verapamil also caused relaxation of K+ (80 mM) and PE (1 μM) induced contractions with respective EC50 1.054 μM (95% CI: 0.45–5.68) and 0.764 μM (95% CI: 0.33–68.8). The aqueous fraction of (Hh.Aq) partially exerted relaxation of K+ (80 mM) and PE (1 μM) induced contractions on aortic preparation (Figure 5).
Figure 5. Effect of (A) crude extract (Hh.Cr), (B) Ethyl acetate fraction (Ea.Hh), (C) Aqueous fraction (Ea.Aq), and (D) verapamil on K+ induced contraction and effect of (E) crude extract (Hh.Cr), (F) Ethyl acetate fraction (Ea.Hh), (G) Aqueous fraction (Ea.Aq), and (H) verapamil on PE 1 μM Induced Contraction on rabbit aorta preparations. Effect of crude extract (Hh.Cr) Ethyl acetate fraction (Ea.Hh) and Aqueous fraction (Ea.Aq) on (I) K+ (80 mM) Induced Contraction and (J) PE 1 μM Induced Contraction on aortic jejunum preparations. (K) Effect of verapamil on PE 1 μM and K+ Induced Contraction on rabbit tracheal preparations. Values are expressed as mean ± SEM.

2.6. Effect on Atria Preparations

The crude extract (Hh.Cr) and its ethyl acetate (Hh.Ea) fraction caused the negative chronotropic effect (i.e., decrease in heart rate) and negative inotropic effect (i.e., force of contraction) on atrium preparation [12]. Hh.Cr and its Hh.Ea fraction showed negative inotropic effect within concentration range 0.01–5.0 mg/mL with EC50 0.9 mg/mL (95% CI: 0.375–1.356 mg/mL; n = 3) and 0.01–3.0 mg/mL with EC50 0.7 mg/mL (95% CI: 0.265–0.586 mg/mL; n = 3), respectively. Hh.Cr and its Hh.Ea fraction showed the negative chronotropic effect within concentration range 0.01–5.0 mg/mL with the EC50 0.5 mg/mL (95% CI: 0.406–0.680 mg/mL; n = 3) and 0.01–3.0 mg/mL with the EC50 value calculated to be 0.4 mg/mL (95% CI: 0.106–0.050 mg/mL; n = 3), respectively. Similarly, verapamil also showed negative inotropic and chronotropic effect with concentration range 0.01–1.0 mg/mL with EC50 value of 0.053 μM (95% CI: 0.034–0.084 μM; n = 3) and 0.01–0.3 mg/mL with EC50 0.037 μM (95% CI: 0.024–0.045 μM; n = 3). The aqueous fraction (Hh.Aq) exerted partially negative inotropic and chronotropic effect on atrium preparation with in concentration range 3–10 mg/mL with EC50 1.02 mg/mL (95% CI:
0.485–0.856 mg/mL; n = 3) and 3–10 mg/mL with 1.14 mg/mL (95% CI: 0.575–1.756 mg/mL; n = 3), respectively (Figure 6).

Figure 6. (A) Spontaneous contraction. Effect of (B) crude extract (Hh.Cr), (C) Ethyl acetate fraction (Ea.Hh), and (D) Aqueous fraction (Ea.Aq) on spontaneous contraction rabbit paired atrium preparations. (E) Effect of verapamil on spontaneous contraction rabbit paired atrium preparations. Effect of crude extract (Hh.Cr) Ethyl acetate fraction (Ea.Hh) and Aqueous fraction (Ea.Aq) on (F) K⁺(80mM)-induced contraction. (G) force of contraction. (H) Effect of verapamil on the force of contraction and heart rate on rabbit atrium preparations. Values are expressed as mean ± SEM.

2.7. Antiperistalsis Activity

The crude extract (Hh.Cr) showed a significant antiperistalsis response in mice with less distance traveled by charcoal meal as compared to control (33 ± 2.3%). The group was treated with 400 mg/kg of Hh.Cr and CCh (3 mg/kg) and peristaltic movements were significantly decreased by 1.2 ± 0.37 and 8.6 ± 1.8, respectively (Figure 7).
Plants 2022, 10, x FOR PEER REVIEW... with suitable force field make docking calculation of compounds more acceptable with accuracy (Table 2) [12–14].

2.8. Antidiarrheal Activity

The crude extract (Hh.Cr) showed a significant antidiarrheal response in rats with fewer wet fecal masses than control (15.60 ± 1.4). The group was treated with 400 mg/kg of Hh.Cr and loperamide (3 mg/kg) showed highly significant anti-diarrheal effect 1.2 ± 0.37 and 0.8 ± 0.37, respectively (Figure 7).

2.9. Anti-Inflammatory Activity

The crude extract (Hh.Cr) showed a significant anti-inflammatory response in rats with inhibition of edematous volume of hind paw as compared to control (2.93 ± 0.2 mL) at maximum duration. The Hh.Cr inhibited the paw edema at 100 mg/kg as 0.96 ± 0.08 mL, 1.10 ± 0.01 mL, 1.16 ± 0.01 mL, 1.12 ± 0.015 mL, and 1.23 ± 0.01 mL at 0, 1, 2, 3, and 4 h duration, respectively, whereas at dose 300 mg/kg, it showed maximum inhibition, i.e., 0.87 ± 0.01 mL, 0.86 ± 0.01 mL, 0.86 ± 0.03 mL, 0.91 ± 0.01 mL, 1.04 ± 0.001 mL, and 1.15 ± 0.02 mL at 0, 1, 2, 3, and 4 h duration, respectively. Hh.Cr inhibited the edematous volume as similar to the aspirin, i.e., 1.05 ± 0.02 mL (Figure 7).

2.10. In Silico Studies

The docking calculations are beneficial to predict ligand pose within the binding site of the target protein. The involvement of physical energies terms (i.e., solvation energy) with suitable force field make docking calculation of compounds more acceptable with accuracy (Table 2) [12–14].
Table 2. Binding energies (kcal/mol) of compounds with Muscarinic-3 (MM3, PDB ID: 4U14), Cyclooxygenase-2 (COX-2, PDB ID:5IKQ) and lipoxygenase 5 (LOX-5, PDB ID: 6N2W) receptors calculated by Prime MMGBSA.

| Name (PubChem ID) | Docking Score | \( \Delta G_{\text{Binding}} \) | Log \( K_i \) (µMolar) | \( \Delta G_{\text{Coulomb}} \) | \( \Delta G_{\text{Covalent}} \) | \( \Delta G_{\text{Hbond}} \) | \( \Delta G_{\text{Lipophilic}} \) | \( \Delta G_{\text{Solv GB}} \) | \( \Delta G_{\text{vdW}} \) | Residue-Ligand Interactions with Distance (Å) |
|-------------------|---------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------------------------------------|
| Arctiin (100528)  | −11.63        | −60.79          | −23.17          | 10.56           | −1.22           | −42.47          | 47.40           | −55.32          |                  | Asn513 (2.46), Leu225 (1.77), C-H Bond: Thr231 (2.58), Tyr529 (2.99), \( \pi \)-Donor Bond: Trp525 (2.71), Trp525 (2.66) |
|                   | −9.72         | −46.56          | −16.99          | −16.92          | 6.57            | −0.68           | −30.61          | 31.10           | −34.45          | Ala238 (1.64), C-H Bond: Thr234 (3.03), Ile222 (2.77), Leu225 (2.77), Leu225 (2.65), Tyr148 (2.40) |
| Catechin (9064)   | −7.59         | −52.22          | −19.45          | −29.22          | 2.89            | −2.92           | −13.93          | 27.23           | −34.12          | Tyr148 (2.05), Ile222 (2.39), Ile222 (3.03), Ser226 (1.92), Ser226 (1.80) |
| Chlorojanerin (182408) | −7.13       | −43.68          | −15.74          | −20.79          | 2.92            | −1.98           | −19.31          | 33.51           | −38.02          | Tyr127 (1.87), Tyr148 (2.30), Asn513 (3.02), Asn513 (3.03), Asn526 (2.03), Ser226 (2.60), C-H Bond: Leu225 (2.63), Leu225 (2.55), Ser226 (2.55) |
| Cynaropicrin (119093) | −6.76       | −48.69          | −17.92          | −19.54          | 1.54            | −1.63           | −18.37          | 26.11           | −36.81          | Tyr148 (3.00), Ile222 (2.49), Asn526 (1.77), Leu225 (1.92), Thr231 (2.64) |

Hydrogen Bonds: Cys532 (5.42), Tyr506 (3.99), Tyr529 (4.91), Tyr529 (3.98), Leu225 (4.98)

Hydropobic Bonds: Trp503 (5.58), Trp525 (5.37), Tyr148 (5.74)
| Name          | (PubChem ID) | Docking Score | \( \Delta G_{\text{Binding}} \) (\( \mu \text{Molar} \)) | \( \Delta G_{\text{Coulomb}} \) | \( \Delta G_{\text{Covalent}} \) | \( \Delta G_{\text{Hbond}} \) | \( \Delta G_{\text{Lipophilic}} \) | \( \Delta G_{\text{Solv GB}} \) | \( \Delta G_{\text{vdW}} \) | Residue-Ligand Interactions with Distance (Å)                                                                 |
|---------------|--------------|---------------|----------------|-----------------|----------------|----------------|----------------|----------------|----------------|-------------------------------------------------------------------------------------------------------------------|
| Arctiin       | (100528)     | -8.49         | -41.01          | -14.58          | -21.01         | 10.60          | -2.56          | -23.77         | 33.40          | -36.96 \( \pi-\pi \) T shaped Bond: Tyr11 (5.32), Alkyl Bond: Ala112 (5.50), Val89 (4.95), Leu93 (4.90), Val117 (4.37), Leu109 (4.79), Ile113 (5.11), \( \pi-Alkyl \) Bond: Tyr116 (4.01), Val89 (3.76), Le113 (4.71) |
| Arctigenin    | (64981)      | -7.37         | -27.91          | -8.89           | -5.55          | 18.02          | 0.00           | -31.09         | 26.83          | -35.44 \( \pi-\sigma \) Bond: Val117 (2.48), Alkyl Bond: Arg121 (4.83), Val350 (4.80), Leu353 (5.46), Val89 (4.59), Leu93 (5.01), \( \pi-Alkyl \) Bond: Val350 (5.15), Leu353 (4.99), Val524 (4.56), Ala528 (4.24) |
| Cynaropicrin  | (119093)     | -4.28         | -35.97          | -12.39          | -11.96         | 3.10           | -1.10          | -18.58         | 17.86          | -25.30 \( \pi-\pi \) T shaped Bond: Tyr116 (5.65), \( \pi-\pi \) Stack Bond: Val89 (5.41), \( \pi-Alkyl \) Bond: Tyr116 (5.22) |
| Catechin      | (9064)       | -2.84         | -11.87          | -1.93           | 2.05           | 4.15           | -0.61          | -11.82         | 15.82          | -18.71 \( \pi-\pi \) T shaped Bond: Tyr116 (5.65), \( \pi-\pi \) Stack Bond: Tyr116 (5.65), \( \pi-Alkyl \) Bond: Val89 (4.00), \( \pi-Alkyl \) Bond: Tyr116 (5.27), Val89 (4.80), Pro84 (5.20) |

**Cyclooxygenase-2 (COX-2, PDB ID: 5IKQ)**

**Lipoxygenase 5 (LOX-5, PDB ID: 6N2W)**
Table 2. Cont.

| Name (PubChem ID) | Docking Score | ΔG<sub>Binding</sub> | Log K<sub>i</sub> (µMolar) | ΔG<sub>Coulomb</sub> | ΔG<sub>Covalent</sub> | ΔG<sub>Hbond</sub> | ΔG<sub>Lipophilic</sub> | ΔG<sub>Solv GB</sub> | ΔG<sub>vdW</sub> | Residue-Ligand Interactions with Distance (Å) |
|-------------------|--------------|----------------------|-----------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|-----------------------------------------------|
| Catechin (9064)   | -4.95        | -30.81               | -10.15                      | -22.76               | 5.66                 | -2.38                | -15.10               | 39.78                | -32.68               | Arg<sup>596</sup> (2.34), His<sup>600</sup> (1.80), <br>π-Donor Hydrogen Bond: His<sup>372</sup> (3.10) |
| Arctigenin (64981)| -4.84        | -42.94               | -15.42                      | -28.08               | 3.66                 | -3.06                | -18.99               | 34.43                | -29.61               | Arg<sup>596</sup> (2.57), Arg<sup>596</sup> (1.88), His<sup>600</sup> (1.82) |
| Cynaropicrin (119093)| -3.45         | -14.54               | -3.09                       | -13.54               | 2.95                 | -0.81                | -17.02               | 46.96                | -33.09               | His<sup>367</sup> (2.76), Ile<sup>673</sup> (1.84),<br>C-H Bond: Ala<sup>410</sup> (2.98) |
| Chlorojanerin (182408)| -3.30        | -32.60               | -10.93                      | -3.30                | 0.38                 | -0.62                | -13.65               | 19.69                | -35.10               | Thr<sup>427</sup> (2.78), Arg<sup>596</sup> (1.77),<br>H<sup>is600</sup> (2.15),<br>C-H Bond: His<sup>367</sup> (2.97),<br>H<sup>is600</sup> (2.56), Pro<sup>569</sup> (2.73) |

ΔG<sub>Binding</sub>: Binding free energy. Log K<sub>i</sub>: Logarithmic of Inhibition Constant (K<sub>i</sub>). ΔG<sub>Coulomb</sub>: Coulomb binding energy. ΔG<sub>Covalent</sub>: Covalent binding energy. ΔG<sub>Hbond</sub>: Hydrogen bonding energy. ΔG<sub>Lipophilic</sub>: Lipophilic binding energy. ΔG<sub>Solv GB</sub>: Generalized born electrostatic solvation energy. ΔG<sub>vdW</sub>: Van der Waals forces energy. H<sup>is600</sup> (5.03), Ala<sup>603</sup> (4.88)
Molecular docking for Muscarinic M3 receptor: The selected compounds were studied against muscarinic M3 (MM3, PDB ID: 4U14)) for antispasmodic activity (Table 2, Figure 8). Arctiin was predicted with the lowest binding energy ($\Delta G_{\text{bind}}$ = $-60.79$ kcal/mol) with hydrophobic energies $\Delta G_{vdW}$ ($-55.32$ kcal/mol) and $\Delta G_{\text{Lipo}}$ ($-42.47$ kcal/mol) major contributors to the ligand binding energy. It formed the two $\pi$-donor hydrogen interaction with residue Trp525 and hydrophobic interactions ($\pi-\pi$ Stacked Bond: Trp503; $\pi-\pi$ T shaped Bond: Tyr1148) within the pocket of MM3. Besides these, it also formed the $\pi$-Sulfur interaction with residue Cys532. Arctigenin second to arctiin also found potent with have ligand binding energy ($\Delta G_{\text{bind}}$ = $-46.56$ kcal/mol) mainly contributed with hydrogen bond interaction ($\Delta G_{\text{Hbond}}$: $-0.68$ kcal/mol) and hydrophobic interaction ($\Delta G_{vdW}$: $-34.45$ kcal/mol and $\Delta G_{\text{Lipo}}$: $-30.61$ kcal/mol). It formed hydrophobic $\pi-\pi$ T-shaped interaction with residue Trp503 and Trp525 within the protein cleft. Moreover, catechin has the lowest binding energy ($\Delta G_{\text{bind}}$: $-52.22$ kcal/mol) with $\Delta G_{vdW}$ ($-34.12$ kcal/mol) and $\Delta G_{\text{Lipo}}$ ($-13.93$ kcal/mol) and formed $\pi-\pi$ T shaped interaction with residue Tyr506. The ranking orders of ligands with COX-2 is given below: arctiin > arctigenin > catechin > chlorojanerin > cynaropicrin.

Molecular docking for cyclooxygenase-2 enzyme: The selected compounds were studied against cyclooxygenase-2 enzyme (COX-2, PDB ID:5IKQ) for anti-inflammatory activity (Table 2, Figure 8). Arctiin was predicted with the lowest binding energy ($\Delta G_{\text{bind}}$: $-41.01$ kcal/mol) among the selected compounds. As mentioned earlier, Van der Waals ($\Delta G_{vdW}$) and lipophilic interactions ($\Delta G_{\text{Lipo}}$) are significant contributors to the ligand binding energy. It was observed that the binding energies value of $\Delta G_{vdW}$ was $-36.96$ kcal/mol, and $\Delta G_{\text{Lipo}}$ was $-23.77$ kcal/mol, whereas hydrogen bond ($\Delta G_{\text{Hbond}}$) energy contribution was $-2.56$ kcal/mol. It also formed hydrophobic interactions $\pi-\pi$ T shaped interaction with Tyr11. Arctigenin second to arctiin in docking score was found with potential hydrophobic interactions within hydrophobic clefts of COX-2. The ligand binding energy of arctigenin ($\Delta G_{\text{bind}}$: $-27.91$ kcal/mol) was driven mainly by these hydrophobic interaction energies; $\Delta G_{vdW}$ ($-35.44$ kcal/mol) and $\Delta G_{\text{Lipo}}$ ($-31.09$ kcal/mol) and formed hydrophobic $\pi-\sigma$ interaction with Val117. The ranking orders of ligands with COX-2 are given below: arctiin > arctigenin > catechin > chlorojanerin > cynaropicrin.

Molecular docking for lipoxigenase-5 enzyme: The selected compounds were studied against lipoxgenase-2 enzyme (LOX-5, PDB ID: 6N2W) for anti-inflammatory activity (Table 2, Figure 8). The contribution of hydrophobic interactions in ligand binding energy was more abundant within pockets of LOX-5. Arctigenin has higher ligand binding energy ($\Delta G_{\text{bind}}$: $-42.94$ kcal/mol) but ranks third in the docking score. The ligand binding energy contributed with hydrogen bond interaction ($\Delta G_{\text{Hbond}}$: $-3.06$ kcal/mol) and hydrophobic interaction ($\Delta G_{vdW}$: $-29.61$ kcal/mol and $\Delta G_{\text{Lipo}}$: $-18.99$ kcal/mol). It also formed hydrophobic interactions ($\pi-\pi$ Stacked Bond: His372) within the pocket of LOX-5. Arctiin ranked at first in position docking score with ligand binding energy ($\Delta G_{\text{bind}}$: $-30.76$ kcal/mol) which mainly contributed from hydrophobic interaction energies $\Delta G_{vdW}$ ($-46.53$ kcal/mol and $\Delta G_{\text{Lipo}}$: $-16.17$ kcal/mol), whereas hydrogen bond ($\Delta G_{\text{Hbond}}$) energy contribution was $-2.11$ kcal/mol. Besides hydrophobic interaction, arctigenin and arctiin also formed electrostatic charge interaction with residue Arg596 and Ile673 within the cleft of COX-2, respectively. Catechin have ligand binding energy ($\Delta G_{\text{bind}}$: $-30.81$ kcal/mol) mainly contributed with hydrogen bond interaction ($\Delta G_{\text{Hbond}}$: $-2.38$ kcal/mol) and hydrophobic interaction ($\Delta G_{vdW}$: $-32.68$ kcal/mol and $\Delta G_{\text{Lipo}}$: $-15.10$ kcal/mol). Catechin formed the $\pi$-donor hydrogen interaction with residue His372 and hydrophobic interactions ($\pi-\pi$ Stacked Bond: His367; $\pi-\pi$ T shaped Bond: His372, Trp599) within the pocket of LOX-5. The ranking order of ligands with COX-2 is given below: arctiin > catechin > arctigenin > cynaropicrin > chlorojanerin.
3. Discussion

*Himalaiella heteromalla* has a potential pharmacological role in the management of various diseases. This research was employed to investigate its pharmacological characteristics. The presence of alkaloids, glycosides, triterpenoids, flavonoids, saponins, sesquiterpene, which play a vital role in the pharmacological potential of *Himalaiella heteromalla*. The HPLC results indicate the presence of gallic acid, catechin, HB acid, and vanillin acid. Gallic acid (3,4,5 trihydroxybenzoic acid), a natural polyphenol product, has anti-oxidant, anti-inflammatory, antimicrobial, and radical scavenging activities. Gallic acid is used as a spasmolytic effect on smooth muscle isolated jejunum tissues and trachea by calcium chan-
Plants 2022, 11, 78

nel blocking activity [15]. Gallic acid is used as an antispasmodic in diarrhea [16]. Gallic acid possesses an anti-inflammatory effect [17]. Catechin abundant flavonoid present in plants, it reported for several gastrointestinal, respiratory, and inflammatory disorders [18–20]. Vanilla acid and HB acid are polyphenolics used for gastrointestinal, respiratory, and cardiovascular disorders by spasmylytic effects on isolated tissues of the jejunum, trachea, and aorta [20]. The water content in *H. heteromalla* play a vital role in the biological activities, so it is more important to measure the water content in *H. heteromalla* therefore, infra red radiation can be used to measure water content determination [21].

*Himalaiella heteromalla* crude extract (Hh.Cr) was studied on isolated jejunum preparations to elaborate the mechanism of *H. heteromalla* in gastrointestinal diseases. It is reported that jejumum preparations have rhythmic contractions due to the influx of calcium ions and potassium ions through their respective ions channels. *H. heteromalla* crude extract and its fraction ethyl acetate exerted spasmylytic response in dose concentration when exposed to spontaneous contraction of jejunum preparations [22]. Thus, *H. heteromalla* crude extract and its fraction ethyl acetate showed the antispasmodic response by suppressing rhythmic contractions in jejunum preparations. These results indicate that *H. heteromalla* crude extract and its fraction ethyl acetate decrease or blockade the cytoplasmic free Ca$^{++}$ ions through the blockade of voltage-dependent calcium ion channels. As a result, activation of calmodulin and other contractile proteins, i.e., actin and myosin, does not occur [23]. *H. heteromalla* crude extract and its fraction ethyl acetate and aqueous were exposed to K$^+$ (80 mM)-induced contractions on jejunum preparations, *H. heteromalla* crude extract and its fraction ethyl acetate relaxed the K$^+$ (80 mM)-induced contractions in dose concentration manner in a tissue organ bath. It was previously reported that K$^+$ (80 mM) induces contractions to cause cell depolarization by the influx of calcium ions into the cell through the voltage-gated L-type calcium ion channel [24]. Similar to verapamil, any substance inhibited K$^+$ (80 mM)-induced contractions were considered calcium channel blockers (CCB). Thus, *H. heteromalla* crude extract and its fraction ethyl acetate blockade the calcium influx into the cell by alternating or binding with voltage-dependent calcium channels. Furthermore, calcium concentration–response curves (CRCs) were constructed on pretreated Hh.Cr jejunum preparations to confirm the calcium channel blockade activity of Hh.Cr in a tissue organ bath. The results showed that partial blockade with the rightward parallels dose–response curves at low doses while completely blocking the dose–response curves at 0.3 mg/m. Thus, *Himalaiella heteromalla* exhibited a strong calcium antagonistic effect [25].

To evaluate another possible mechanism of *H. heteromalla* crude extract on the gastrointestinal tract, Hh.Cr was studied in antiperistalsis and antidiarrheal in vivo models. *H. heteromalla* crude extract showed the antispasmodic response by inhibiting the traveling of charcoal meal in antiperistalsis activity. *H. heteromalla* crude extract also inhibited diarrheal response in castor oil-induced diarrhea. It decreased the wet feces by inhibiting the electrolyte and water imbalance that may cause diarrhea in rats [26].

*H. heteromalla* crude extract and its fractions ethyl acetate and aqueous were tested for possible bronchodilator activity against CCh (1 µM) and K$^+$ (80 mM)-induced contractions on tracheal preparations. The results showed that *H. heteromalla* crude extract and its fractions ethyl acetate exhibited relaxant response against CCh (1 µM) and K$^+$ (80 mM)-induced contractions, but a partial relaxant effect was observed by the aqueous fraction. However, EC_{50} of *H. heteromalla* crude extract and its fractions ethyl acetate against K$^+$ (80 mM)-induced contractions that were more minor than CCh-induced contractions, similar to that of verapamil. CCh is a cholinergic agonist which causes smooth muscle contraction through activation of muscarinic receptors. Hence, *H. heteromalla* crude extract and its fractions ethyl acetate showed bronchodilator response was found due to Ca$^{++}$ ion channel and muscarinic receptor blockade. Nowadays, Ca$^{++}$ channel blockers and muscarinic antagonists are used to treat the relief from respiratory diseases such as asthma [27,28].

*H. heteromalla* crude extract and its fractions ethyl acetate and aqueous were tested for possible vasorelaxant activity against PE (1 µM) and K$^+$ (80 mM)-induced contractions on
aortic preparations. The results showed that *H. heteromalla* crude extract and its fractions ethyl acetate exhibited a relaxant response against PE (1 µM) and K⁺ (80 mM)-induced contractions, similar to verapamil. *H. heteromalla* aqueous fraction partially relaxed the PE and K⁺ (80 mM) induced contractions. Relaxation of the PE (PE) and K⁺ (80 mM)-induced contractions indicates a blockade of intracellular Ca²⁺ influx by blocking Ca²⁺ channels. Ca²⁺ channel blockers are essential drugs used clinically to manage angina and hypertension [29,30].

*H. heteromalla* crude extract and its fractions ethyl acetate and aqueous were tested on paired atrium for possible effects on force and rate of atrial contractions. *H. heteromalla* crude extract and its fractions ethyl acetate and aqueous showed cardio suppressant response via blocking calcium channels, hence Hh.Cr and its fractions were found with adverse inotropic and chronotropic effects on the paired atrium [31].

*Himalaiella heteromalla* crude extract was tested for anti-inflammatory activity. It was found that Hh.Cr blocked the release of inflammatory mediators in rat paw edema and other models. It is reported that carrageenan acetic acid and formalin release inflammatory mediators such as bradykinin, histamine, TNF, IL-1b, IL-6, PEG2, and TNF were blocked by crude extract of crude extract *Himalaiella heteromalla*. The reduction in inflammatory mediators by carrageenan, inducing the rat’s paw edema model to show that Hh.Cr inhibits factors that cause inflammation and swelling. On the other side, pain sensation is a significant indicator in the inflammation process, which Hh blocked Cr, so that it exhibited analgesic activity. This anti-inflammatory result was compared with standard drug analgesic aspirin, reducing all models' inflammation and pain sensations. The comparative results in between aspirin and Hh.Cr showed that Hh.Cr exhibited the same potential as aspirin to reduce the pain and inflammation via blocking inflammatory mediators [32].

Molecular docking is a helpful tool to predict the possible mechanism of actions of the selected compounds of various pharmacological studies—the present study correlated and defined antispasmodic and anti-inflammatory activities of *Himalaiella heteromalla*. The five compounds of *H. heteromalla* were studied for cyclooxygenase 2, lipoxygenase 5, and muscarinic M3 receptor. The docking calculations of these compounds indicate the presence of antispasmodic and anti-inflammatory activities, which were previously proven in experimental studies. Arctiiin and arctigenin were more potent compounds responsible for these activities. These results conclude that these compounds interact with cyclooxygenase 2, lipoxygenase 5, and muscarinic M3 receptor to exert the activity. As mentioned earlier, Gao et al. [4] reported that arctigenin and arctiin have anti-inflammatory and vasodilation properties and help treat acute lung injury, local edema, brain trauma, and colitis. These studies support the potent results of arctigenin and arctiin in silico studies against major inflammatory proteins COX-2 and LOX-5.

4. Materials and Methods

4.1. Extract Preparation

*Himalaiella heteromalla* (D.Don) Raab-Straube was collected from hilly areas of Islamabad and identified by Dr. Zafarullah Zafar, taxonomist, Institute of Pure and Applied Biology, and submitted with voucher no: http://www.theplantlist.org/tpl1.1/record/gcc-138921 dated 18 June 2018. Plant material was ground through a herbal grinder for coarse powder, then powder (1 kg) was macerated in methanol aqueous (70:30) for maceration in an amber color glass bottle for three days at room temperature and periodically shaken 3–4 times a day. The solvent was filtered to remove plant debris with muslin cloth and Whatman-1 filter paper. This procedure was replicated thrice, and the filtrate obtained by all steps was combined and processed in a rotary evaporator (BUCHI) under reduced pressure at 36 ± 2 °C to obtain a brownish colored semi-solid (Hh.Cr) and stored at −20 °C in an airtight jar with a percentage yield of 12%. The Hh.Cr (20 g) was subjected to solvent-solvent extraction with ethyl acetate and distilled water to produce an ethyl-acetate fraction (Hh.Ea) and aqueous fraction (Hh.Aq) with approximately 5.5% and 40% yield, respectively.
*H. heteromalla* crude extract (Hh.Cr) and its fractions were moderately soluble in aqueous. All dilutions were prepared fresh on the day of the experiment.

4.2. Animal Housing

Both sexes of albino mice (weight: 20–30 g), rats (weight: 150–200 g), and rabbits (weight: 1–1.8 kg) were used in this study and kept under controlled housing conditions with a temperature of 23 ± 3 °C in the animal house of the Faculty of Pharmacy, Bahauddin Zakariya University, Multan. Before the experiment, animals were deprived of food overnight but had free access to water. For in vitro experimentation, rabbits were sacrificed following a blow, while mice and rats were killed by cervical dislocation. All the experiments were performed under rules specified by the Institute of Laboratory Animal Resources, Commission on Life Sciences (NRC, 1996) endorsed by the Ethical Committee of Bahauddin Zakariya University, Multan.

4.3. Chemicals

All the chemicals used in this study have high purity with research-grade quality. Acetylcholine (Ach), aspirin, carbamylcholine chloride HCl, Carbachol (CCh), verapamil HCl, phenylephrine (PE) were purchased from Sigma Chemical Company, St. Louis, MO, USA. While Potassium dihydrogen phosphate, magnesium chloride, sodium bicarbonate, sodium chloride, magnesium sulfate, sodium dihydrogen phosphate, calcium chloride, potassium chloride, ethylenediaminetetraacetic acid (EDTA), glucose were purchased from Merck, Dermstadat Germany. Furthermore, loperamide, and dicyclomine were supplied by Sigma Chemical company, St. Louis, MO, USA).

4.4. Qualitative Phytochemical Detection

The qualitative phytochemical investigation of *H. heteromalla* was performed to identify alkaloids, glycosides, anthraquinones, terpenes, saponins, flavonoids, and phenols.

4.5. HPLC Separation of Phenolic Acids and Flavonoids

The phenolic acids and flavonoids components in *Himalaiella heteromalla* were quantified by developing a binary gradient solvent system to run in Chromera HPLC system (Perkin Elmer, Houston, TX, USA) consisting of Flexer Binary Liquid chromatography (LC) pump coupled with UV/Vis LC Detector (Shelton, CT, USA) which was operated with the help of a software. HPLC system consisted of a C-18 column (250 × 4.6 mm internal diameter) with a thickness of 5 µM film. The mobile phase consisted of solvent A (methanol (30): acetonitrile (70)) and solvent B (0.5% glacial acetic acid in double-distilled water), mobile phase run at flow rate 0.08 mL/min, and data was recorded at 275 nm of UV spectra. The peaks and retention times of phenolic acids and flavonoids of *H. heteromalla* were matched with external standards to quantify the components [12]. The resolution and separation factor was used to determine HPLC separation efficiency.

4.6. In Vitro Experiments

The physiological response of tissues was recorded with isotonic and force-displacement isometric transducers amplified with acquisition system Power Lab (AD Instruments, Bella Vista, NSW, Australia) coupled with a computer having Lab chart Pro. The effect was taken as percent change on the part of test substance recorded instantly preceding a dose of test substance [22].

4.6.1. Isolated Rabbit Jejunum Preparation

The jejunum was dissected from a rabbit; the adhesive fatty tissues were carefully removed, and then ~2 cm long piece of jejunum was prepared. This tissue was hung in an organ bath containing Tyrode’s solution with a continuous supply of carbogen (95% O₂ + 5% CO₂) at 37 °C and equilibrated for 30 min. Acetylcholine (1 µM) was added to spontaneous rhythmic contractions of jejunum for control response and washed it. The
Hh.Cr was added cumulatively for antispasmodic effect. The spontaneous contractions of the jejunum preparation were exposed to $K^+$ (80 mM) induced contraction for estimation of CCB activity [33]. The extract was exposed to calcium concentration response curves (CRCs) for further confirmation. The jejunum preparation was stabilized in Tyrode’s solution, subsequently replaced with calcium-free Tyrode’s solution with EDTA (0.1 mM) to remove calcium from tissue. Afterward, with an incubation duration of 40 min, two superimposable control calcium CRCs were constructed in an organ bath, then tissue was incubated with the plant extract for one h, and calcium CRCs were obtained and compared to control. The calcium CRCs were recorded in the presence of different concentrations of plant extract.

4.6.2. Isolated Rabbit Tracheal Preparations
The trachea was dissected from a rabbit for bronchodilator activity, and the 2 mm tracheal ring tissue was prepared. A longitudinal incision was made opposite the smooth muscle layer to form a strip. This tracheal preparation was hung in an organ bath containing Krebs’s solution with a continuous supply of carbogen at 37 °C. Preload tension (1 g) was applied and allowed to equilibrate for 60 min prior to the dose of any drug. The tracheal preparation was exposed to CCh (1 µM), and $K^+$ (80 mM) induced contraction for bronchodilator activity in a cumulative manner.

4.6.3. Isolated Rabbit Paired Atria Preparations:
The heart was dissected from a rabbit for cardiac activity, and the ventricles were carefully removed to isolate paired atria. This atrium preparation was hung in an organ bath containing Krebs’s solution with a continuous supply of carbogen at 34 °C. Then, 1 g preload tension was applied and allowed to equilibrate for 30 min prior to the dose of any drug. The isolated atrium preparation was exposed for possible cardiac effects in a cumulative fashion, and changes in rate and force of contractions were observed.

4.6.4. Isolated Rabbit Aorta Preparations
For vasorelaxant activity, the thoracic aorta was dissected from a rabbit, carefully removed the adhesive fatty tissues, and prepared 2–3 mm aortic rings. This aortic preparation was hung in an organ bath containing Krebs’s solution with a continuous supply of carbogen. Preload tension (2 g) was applied and allowed to equilibrate for 60 min prior to the dose of any drug. The isolated aortic preparation was exposed to $H. heteromalla$ for possible vasorelaxant effects in a cumulative manner. Further to define the possible mechanism, $H. heteromalla$ was challenged to PE (1 µM), and $K^+$ (80 mM) induced contraction for the possible activity of $H. heteromalla$ in a cumulative manner.

4.7. In Vivo Activities
4.7.1. Antiperistalsis Activity
Antiperistalsis activity was performed according to the method prescribed by Wahid et al. [12]. Mice (25) of either sex were divided into 5 groups, i.e., control (0.9% normal saline), standard drug (CCh10 mg/kg), and $H. heteromalla$ doses (100, 200, and 400 mg/kg). After 15 min of administering the test or standard material orally, each animal received 0.3 mL of the charcoal meal (10% gum acacia, 20 starch, and 10% vegetable charcoal) in distilled water. Thirty minutes later, mice were killed, and the abdomen was incised to excise the whole small intestine. The distance from the pylorus region was measured to the front of the charcoal meal.

4.7.2. Antidiarrheal Activity
The antidiarrheal activity was performed according to the method prescribed by Wahid et al. [12] with modifications. Mice (20) of either sex were divided into five groups, i.e., negative control (0.9% normal saline), standard drug (loperamide 10 mg/kg), and $H. heteromalla$ doses (100, 200, and 400 mg/kg). After 30 min of dose administration (p.o.), animals received the castor oil (10 mL/kg p.o.) and were observed for six hours in cages.
with a white paper surface with adsorbent properties. The percent inhibition of wet fecal
was calculated.

4.7.3. Carrageenan-Induced Rat’s Hind Paw Edema Method

The anti-inflammatory activity was performed [32,34] on 25 rats of either sex divided
into 5 groups, i.e., control (0.9% normal saline) standard drug (aspirin 10 mg/kg), and H. heteromalla
doses (100, 200, and 400 mg/kg). After 30 min of dose administration (p.o),
edema was induced by injecting 1% carrageenan in the right hind paw’s sub-planter region
and measuring the edema size at up to 4 h through a plethysmometer. The percentage of
edema inhibition was calculated.

4.8. In Silico Studies

In silico studies were performed according to the method previously reported by
Wahid et al. [12] and Sirous et al. [13].

Ligand Preparation: The 2D structures of HPLC quantified phytocompounds were
retrieved from PubChem (https://pubchem.ncbi.nlm.nih.gov accessed date 20 March
2019) and treated in the LigPrep module of Maestro (Schrodinger suite 2015) to ionization,
minimization, and optimization of ligands. The Epik tool of this module was used to
generate the ionization state of ligands at cellular pH (7.4 ± 0.5) and applied the OPLS3e
force field through the module for minimization and optimization of ligands that produce
the lowest energy conformer of ligands.

Protein Preparation: For molecular docking, the highest resolution X-ray structures of
proteins were downloaded from The Protein Databank (RCSB PDB) (https://www.rcsb.org
accessed date 20 March 2019) and subjected to Protein preparation wizard of Maestro
(Schrodinger suite 2015). This module processed the protein by adding hydrogen atoms to
protein structure, removal of solvents (water) molecules, assigning bond orders, creating
disulfide bonds, filling missing side chains and loops, and generating protonation state
using Epik tool of protein structures for ligands at the cellular level pH (7.4 ± 0.5). After
processing protein structures, these structures were optimized using PROPKA under pH
7.0, and the OPLS3e force field was utilized to perform restrained minimization for energy
minimization and geometry optimization of protein structure.

Molecular Docking and Receptor grid generation: The active sites of protein structures
for molecular docking were defined in the Receptor Grid Generation module of Maestro
(Schrodinger suite 2015). A cubic grid box of each protein was defined with the help of a
literature survey and with a selection of previously bonded ligands of proteins. The length
of the grid box was adjusted to the length of 16 Å. The potential of nonpolar parts of the
receptor was decreased to scaling factor 1.0 Å on Van der Waals radius of nonpolar atoms
of protein having partial atomic charge cut-off 0.25 Å.

For molecular docking, the prepared ligands and protein structures were subjected
to extra precision (XP) mode of Ligand Docking (Glide) module of Maestro (Schrodinger
suite 2015) using pre-generated grid file for receptor. Additionally, 0.80 Å scaling factor
was adjusted for Van der Waals radii with a partial charge cut-off of 0.15 Å. The docking
results were subjected to the Prime MM-GBSA module to calculate the binding energies of
ligands with protein structure using the VSGB solvation model with OPLS3e force field.

Inhibition Constant (Ki): The inhibition constant was determined from the binding free
energy of ligand previously generated from Prime MM-GBSA, according to the following
equation [12]:

\[ \Delta G = -RT \ln(K_i) \text{ or } K_i = e^{(-\Delta G/RT)} \]

where \( \Delta G \) is binding free energy of ligand, \( R \) is gas constant (cal·mol\(^{-1}\)·K\(^{-1}\)), and \( T \) is room
temperature (298 Kelvin).

4.9. Statistical Analysis

The data were expressed as the mean ± standard error of the mean (S.E.M.) and
median effective concentration (EC\(_{50}\)) with a 95% confidence interval (CI). One-way and
two-way ANOVA tests were applied for in vivo experiments. All graphs and data were analyzed with the help of Graph pad prism software (San Diego, CA, USA).

5. Conclusions

*Himalaiella heteromalla* exhibited a more spasmolytic effect in ethyl acetate fraction and caused complete relaxation on isolated jejunum, trachea, aorta, and paired atria, supported with in silico studies. *H. heteromalla* proved various disease management-related activities. Further studies could be taken on *Himalaiella heteromalla* for drug discovery for the welfare of human beings.

Author Contributions: F.S. and S.M. planned the project and worked on statistical analysis of data and results interpretation; S.M. performed the experiments and F.U. worked on in-silico studies; R.A.M., C.C.M., N.B., N.U.-R. and M.R. drafted the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was partially funded by FDI-0013.

Institutional Review Board Statement: Ethical approval was attained from Ethical Committee of Bahauddin Zakariya University, Multan (EC/25-MPHIL-S2018) dated 26 March 2018. Researchers agreed using the approved informed consent documented before their enrolment into study.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The author(s) are very thankful Chairman Department of Pharmacology; Imran for Provision of animal house and lab related facilities.

Conflicts of Interest: Authors announce there are no conflict of interest concerning the publication of this research article.

References

1. Saklani, A.; Hegde, B.; Mishra, P.; Singh, R.; Mendon, M.; Chakrabarty, D.; Kamath, D.V.; Lobo, A.; Mishra, P.D.; Dagia, N.M.; et al. NF-κB dependent anti-inflammatory activity of chlorojanerin isolated from *Saussurea heteromalla*. *Phytomedicine* 2012, 19, 988–997. [CrossRef] [PubMed]
2. Sajad, M.A.; Khan, M.S.; Bahadur, S.; Shuaib, M.; Naeem, A.; Zaman, W.; Ali, H. Nickel phytoremediation potential of some plant species of the Lower Dir, Khyber Pakhtunkhwa, Pakistan. *Limnol. Rev.* 2020, 20, 13–22. [CrossRef]
3. Khatun, S. Antimicrobial activity of tuber extracts of the medicinal plant *coleus forskohlii*. *Plant Cell Biotechnol. Mol. Biol.* 2020, 21, 11–17.
4. Gao, Q.; Yang, M.; Zuo, Z. Overview of the anti-inflammatory effects, pharmacokinetic properties and clinical efficacies of arctigenin and arctiin from *Arctium lappa* L. *Acta Pharmacol. Sin.* 2018, 39, 787–801. [CrossRef]
5. Kang, H.S.; Lee, J.Y.; Kim, C.J. Anti-inflammatory activity of arctigenin from *Forsythiae Fructus*. *J. Ethnopharmacol.* 2008, 116, 305–312. [CrossRef]
6. Hayashi, K.; Narutaki, K.; Nagaoka, Y.; Hayashi, T.; Uesato, S. Therapeutic effect of arctiin and arctigenin in immunocompetent and immunocompromised mice infected with influenza A virus. *Biol. Pharm. Bull.* 2010, 33, 1199–1205. [CrossRef] [PubMed]
7. Cheng, X.; Zhong, F.; He, K.; Sun, S.; Chen, H.; Zhou, J. EHHM, a novel phenolic natural product from *Livistona chinensis*, induces autophagy-related apoptosis in hepatocellular carcinoma cells. *Oncol. Lett.* 2016, 12, 3739–3748. [CrossRef] [PubMed]
8. Rathore, S.; Tiwari, J.K.; Malik, Z.A. Ethnomedicinal survey of herbaceous flora traditionally used in health care practices by inhabitants of dhundursi gad watershed of garhwal himalaya, india. *Glob. J. Res. Med. Plants Indig. Med.* 2015, 4, 65–78.
9. Khare, C.P. (Ed.) *Indian Medicinal Plants*; Springer: New York, NY, USA, 2007; ISBN 978-0-387-70637-5.
10. Kala, C.P. Medicinal plants of the high altitude cold desert in India: Diversity, distribution and traditional uses. *Int. J. Biodivers. Sci. Manag.* 2006, 2, 43–56. [CrossRef]
11. Singh, A.; Lal, M.; Samant, S.S. Diversity, indigenous uses and conservation prioritization of medicinal plants in lahaul valley, proposed cold desert biosphere reserve, India. *Int. J. Biodivers. Sci. Manag.* 2009, 5, 132–154. [CrossRef]
12. Wahid, M.; Saqib, F.; Ahmedah, H.T.; Gavris, C.M.; De Feo, V.; Hogea, M.; Moga, M.; Chicea, R. *Cucumis sativus* L. Seeds Ameliorate Muscular Spasm-Induced Gastrointestinal and Respiratory Disorders by Simultaneously Inhibiting Calcium Mediated Signaling Pathway. *Pharmaceuticals* 2021, 14, 1197. [CrossRef] [PubMed]
13. Sirous, H.; Chemi, G.; Campiani, G.; Brogi, S. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction. *Comput. Biol. Chem.* 2019, 83, 107105. [CrossRef]
14. Kuhn, B.; Kollman, P.A. Binding of a diverse set of ligands to avidin and streptavidin: An accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. *J. Med. Chem.* **2000**, *43*, 3786–3791. [CrossRef]

15. Gilani, A.U.H.; Shah, A.J.; Yaeesh, S. Presence of cholinergic and calcium antagonist constituents in Saussurea lappa explains its use in constipation and spasm. *Phytther. Res.* **2007**, *21*, 541–544. [CrossRef]

16. Chen, J.C.; Ho, T.Y.; Chang, Y.S.; Wu, S.L.; Hsiang, C.Y. Anti-diarrheal effect of Galla Chinensis on the *Escherichia coli* heat-labile enterotoxin and ganglioside interaction. *J. Ethnopharmacol.* **2006**, *103*, 385–391. [CrossRef] [PubMed]

17. Cheng, Y.; Li, X.; Tse, H.F.; Rong, J. Gallic acid-L-leucine conjugate protects mice against LPS-induced inflammation and sepsis via correcting proinflammatory lipid mediator profiles and oxidative stress. *Oxid. Med. Cell. Longev.* **2018**, *2018*, 1081287. [CrossRef]

18. Gilani, A.H.; Ghayur, M.N.; Saify, Z.S.; Ahmed, S.P.; Choudhary, M.I.; Khalid, A. Presence of cholinomimetic and acetylcholinesterase inhibitory constituents in betel nut. *Life Sci.* **2004**, *75*, 2377–2389. [CrossRef] [PubMed]

19. Lanuzza, F.; Occhiuto, F.; Monforte, M.T.; Tripodo, M.M.; D’Angelo, V.; Galati, E.M. Antioxidant phytochemicals of *Opuntia ficus-indica* (L.) Mill. cladodes with potential anti-spasmodic activity. *Pharmacogn. Mag.* **2017**, *13*, S424–S429. [CrossRef]

20. Ghayur, M.N.; Khan, H.; Gilani, A.H. Antispasmodic, bronchodilator and vasodilator activities of (+)-catechin, a naturally occurring flavonoid. *Arch. Pharm. Res.* **2007**, *30*, 970–975. [CrossRef]

21. Zhang, M.; Zhao, C.; Shao, Q.; Yang, Z.; Zhang, X.; Xu, X.; Hassan, M. Determination of water content in corn stover silage using near-infrared spectroscopy. *Int. J. Agric. Biol. Eng.* **2018**, *11*, 143–148. [CrossRef]

22. Saqib, F.; Janbaz, K.H. Rationalizing ethnopharmacological uses of *Alternanthera sessilis*: A folk medicinal plant of Pakistan to manage diarrhea, asthma and hypertension. *J. Ethnopharmacol.* **2016**, *182*, 110–121. [CrossRef] [PubMed]

23. Karaki, H.; Ozaki, H.; Hori, M.; Mitsui-Saito, M.; Amano, K.I.; Harada, K.I.; Miyamoto, S.; Nakazawa, H.; Won, K.J.; Sato, K. Calcium movements, distribution, and functions in smooth muscle. *Pharmacol. Rev.* **1997**, *49*, 157–230. [PubMed]

24. Bolton, T.B. Mechanisms of action of transmitters and other substances on smooth muscle. *Physiol. Rev.* **1979**, *59*, 606–718. [CrossRef]

25. Fleckenstein, A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. *Annu. Rev. Pharmacol. Toxicol.* **1977**, *17*, 149–166. [CrossRef]

26. Yakubu, M.T.; Salimon, S.S. Antidiarrhoeal activity of aqueous extract of *Mangifera indica* L. leaves in female albino rats. *J. Ethnopharmacol.* **2015**, *163*, 135–141. [CrossRef] [PubMed]

27. Janbaz, K.H.; Jan, A.; Qadir, M.I.; Gilani, A.H. Spasmylytic, bronchodilator and vasorelaxant activity of methanolic extract of *Inula britannica* L. and patuletin: In vivo and possible mechanisms studies. *J. Ethnopharmacol.* **2013**, *148*, 299–330. [PubMed]

28. Ghayura, M.N.; Gilani, A.H. A-Adrenergic Receptor Mediated Hypertensive and Vasoconstrictor Effects of Dietary Radish Leaves Seed Extract. *J. Health Sci.* **2005**, *51*, S424–S429. [CrossRef]

29. Ghayur, M.N.; Khan, H.; Gilani, A.H. Antispasmodic, bronchodilator and vasodilator activities of (+)-catechin, a naturally occurring flavonoid. *Arch. Pharm. Res.* **2007**, *30*, 970–975. [CrossRef]

30. Gilani, A.H.; Jabeen, Q.; Ghayur, M.N.; Janbaz, K.H.; Akhtar, M.S. Studies on the antihypertensive, antispasmodic and hepatoprotective activities of the *Carum copticum* seed extract. *J. Ethnopharmacol.* **2005**, *98*, 127–135. [CrossRef]

31. Dehni-Marrakchi, Y.; Kallel, E.; Kallel, M.; Fournier, C.; Ciblat, M.; Hamoudi, S.; Ben Gharbia, S.; Kallel, B.; Baazizi, A.; El Khachfi, F.; Djerbi, F. Antioxidant and antihyperglycemic activities of the *Alternanthera sessilis* seed extract: A folk medicinal plant of Pakistan to manage diabetes mellitus. *J. Ethnopharmacol.* **2016**, *173*, 541–544. [CrossRef] [PubMed]

32. Deliorman Orhan, D.; Hartevioğlu, A.; Küpeli, E.; Yesilada, E. In vivo anti-inflammatory and antinociceptive activity of the crude extract and fractions from *Rosa canina* L. fruits. *J. Ethnopharmacol.* **2007**, *112*, 394–400. [CrossRef]

33. VAN ROSSUM, J.M. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. *Arch. Int. Pharmacodyn. Thér.* **1963**, *143*, 299–330. [PubMed]

34. Zarei, M.; Mohammadi, S.; Komaki, A. Antinociceptive activity of *Inula britannica* L. and patuletin: In vivo and possible mechanisms studies. *J. Ethnopharmacol.* **2018**, *219*, 351–358. [CrossRef]